Inhaled Amikacin for Ventilator Associated Pneumonia (VAP)

The efficacy, safety, and feasibility of inhaled amikacin for the treatment of ventilator associated pneumonia in patients with renal impairment

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201909502649249

Enrollment

Registered

2019-09-30

Start date

2019-09-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Kidney Disease

Interventions

inhaled Amikacin

IV Amikacin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Mechanically ventilated patients with oral endotracheal tube or tracheostomy tube for more than 48h. The patient diagnosed as having VAP during his stay in the intensive care unit based on the CDC criteria for clinical diagnosis of VAP. All patients should have an impaired renal functions either chronic kidney disease defined as glomerular filtration rate less than 90ml/min or acute kidney injury based RIFLE criteria for the classification of acute kidney injury.

Exclusion criteria

Exclusion criteria: Patients under age of 18 years. Pregnancy Extrapulmonary infection. Allergy to aminoglycosides.

Design outcomes

Primary

Measure	Time frame
response to antibiotic treatment Cure” of pneumonia or persisting pneumonia	—

Secondary

Measure	Time frame
Days of ventilation. ; Development of severe sepsis or septic shock. ;Mortality	—

Countries

Egypt

Contacts

Public ContactAhmed Ibrahim

Assisstant lecturer Faculty of medicine alexandria university

amibrahim00@gmail.com00201110778295

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026